Immune System Targets

The term 'Immune System Targets' refers to a broad and diverse category of molecular entities, including receptors, cytokines, enzymes, and checkpoints, that modulate the activity of the immune system (Nature Reviews Drug Discovery, 2021). These targets are central to the development of immunotherapies for a wide range of conditions, such as cancer, autoimmune disorders, and chronic inflammatory diseases (StatPearls, 2023). Common examples include programmed cell death protein 1 (PD-1), tumor necrosis factor (TNF), and various interleukins (IUPHAR/BPS Guide to PHARMACOLOGY). Because this is a collective grouping rather than a specific protein or gene, it does not possess a single set of biochemical properties or a uniform mechanism of action. Instead, it encompasses various pathways involved in immune activation, suppression, and homeostasis. Consequently, drugs interacting with these targets vary significantly in their therapeutic intent and safety profiles, ranging from immune checkpoint inhibitors to anti-inflammatory biologics. The identification and validation of these targets are critical for precision medicine, allowing for the development of therapies that can either stimulate the immune system to attack tumors or suppress it to treat autoimmunity. As research progresses, the list of immune system targets continues to expand, incorporating novel pathways such as the cGAS-STING pathway and various myeloid-cell modulators to address unmet clinical needs.

Other names

Immunotherapeutic targetsImmune-related targetsImmunomodulatory targets

Varies by specific target; includes checkpoint inhibition, cytokine neutralization, and signal transduction modulation.